These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 16808554

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
    Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA.
    Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973
    [Abstract] [Full Text] [Related]

  • 23. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
    Andersohn F, Schade R, Suissa S, Garbe E.
    Stroke; 2006 Jul; 37(7):1725-30. PubMed ID: 16728684
    [Abstract] [Full Text] [Related]

  • 24. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
    Hsiang KW, Chen TS, Lin HY, Luo JC, Lu CL, Lin HC, Lee KC, Chang FY, Lee SD.
    Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
    [Abstract] [Full Text] [Related]

  • 25. NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans.
    Roughead EE, Ramsay E, Pratt N, Gilbert AL.
    Drug Saf; 2008 Jul; 31(11):997-1003. PubMed ID: 18840019
    [Abstract] [Full Text] [Related]

  • 26. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS, Nourjah P, Grosser SC, Graham DJ.
    Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM, Reeves MJ, Whelton A.
    Am J Ther; 2007 Apr; 14(1):3-12. PubMed ID: 17303969
    [Abstract] [Full Text] [Related]

  • 29. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA.
    Lancet; 2004 May 29; 363(9423):1751-6. PubMed ID: 15172772
    [Abstract] [Full Text] [Related]

  • 30. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
    Lévesque LE, Brophy JM, Zhang B.
    CMAJ; 2006 May 23; 174(11):1563-9. PubMed ID: 16670396
    [Abstract] [Full Text] [Related]

  • 31. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
    Brophy JM, Lévesque LE, Zhang B.
    Heart; 2007 Feb 23; 93(2):189-94. PubMed ID: 16849374
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY, Tsai YW, Huang WF.
    Clin Ther; 2009 Nov 23; 31(11):2618-27. PubMed ID: 20110006
    [Abstract] [Full Text] [Related]

  • 34. Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme.
    Harrison-Woolrych M, Herbison P, McLean R, Ashton J, Slattery J.
    Drug Saf; 2005 Nov 23; 28(5):435-42. PubMed ID: 15853444
    [Abstract] [Full Text] [Related]

  • 35. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC.
    Clin Exp Rheumatol; 2001 Nov 23; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [What do we know about the cardiovascular toxicity of the NSAIDs?].
    Sibilia J, Deray G, Montalescot G.
    Presse Med; 2006 Sep 23; 35(9 Spec No 1):1S11-23. PubMed ID: 17078591
    [Abstract] [Full Text] [Related]

  • 39. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK, Castellsague J, Walker AM.
    Pharmacoepidemiol Drug Saf; 2008 Oct 23; 17(10):982-8. PubMed ID: 18711705
    [Abstract] [Full Text] [Related]

  • 40. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM.
    Clin Ther; 2001 Sep 23; 23(9):1478-91. PubMed ID: 11589261
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.